Exploring the Role of Biomarkers in the Early Detection and Diagnosis of Psychiatric Disorders
Keywords:
Biomarkers, Psychiatric Disorders, Early Diagnosis, Neuroinflammation, Depression, Schizophrenia, CRP, IL-6, Mental Health Diagnostics, Personalized Medicine.Abstract
This study examines the use of biomarker in the early detection and diagnosis of psychiatric disorders and its special application to depression, schizophrenia, bipolar disorder, and anxiety disorders. Often a psychiatric illness is diagnosed by observing behavioral characteristics and conducting a clinical interview, but this process of diagnosis can cause delay and inaccurate diagnosis and treatment. The study raises the issue of the lack of objective diagnosis in psychiatry and examines the potential for the use of biological markers to inform earlier clinical intervention. The theoretical perspective of the research is rooted in the Biopsychosocial Model and Neuroinflammatory Theory biomarker analysis and secondary hospital data. The study population was 450 patients and recorded in psychiatric departments of the 3 tertiary hospitals in Lahore and Peshawar from 2021 to 2025. In addition which see psychiatric disorders as a result of interactions between biological, psychological, and environmental factors. Research methodology is quantitative mixed clinical approach which uses to DSM-5 diagnostic reports, biomarkers such as C-reactive protein (CRP), Interleukin-6 (IL-6), cortisol and tumour necrosis factor alpha (TNF-α) were analyzed. When we analysed the data statistically, it was found that high levels of inflammatory markers were strongly correlated with early psychiatric symptoms and were able to predict them with an accuracy of 82%. The results show that screening with biomarkers can help identify these disorders earlier, minimize the risks associated with delayed treatment, and lead to individualized psychiatric treatment. The study provides quantifiable results on diagnostic accuracy, clinical effectiveness, and biomarker validity in mental health evaluations.
References
1. Engel, George L. “The Need for a New Medical Model: A Challenge for Biomedicine.” Science, vol. 196, no. 4286, 1977, pp. 129–136.
2. Haroon, Ebrahim, et al. “Inflammation and Neuropsychiatric Disorders: Mechanisms and Therapeutic Implications.” Neuropsychopharmacology, vol. 37, no. 1, 2012, pp. 137–162.
3. Insel, Thomas R. “Rethinking Schizophrenia.” Nature, vol. 468, no. 7321, 2010, pp. 187–193.
4. Khandaker, Golam M., et al. “Inflammation and Psychosis: Evidence, Mechanisms and Implications.” Journal of Neurology, Neurosurgery & Psychiatry, vol. 86, 2015, pp. 1118–1125.
5. Miller, Andrew H., and Charles L. Raison. “The Role of Inflammation in Depression: From Evolutionary Imperative to Modern Treatment Target.” Nature Reviews Immunology, vol. 16, no. 1, 2016, pp. 22–34.
6. Munkholm, Klaus, et al. “Cytokines in Bipolar Disorder: A Systematic Review and Meta-Analysis.” Journal of Affective Disorders, vol. 144, no. 1–2, 2013, pp. 16–27.
7. Nestler, Eric J., et al. “Neurobiology of Depression.” Neuron, vol. 34, no. 1, 2002, pp. 13–25.
8. Osimo, Efthymios F., et al. “Prevalence of Low-Grade Inflammation in Depression: A Systematic Review and Meta-Analysis.” Molecular Psychiatry, vol. 24, no. 12, 2019, pp. 1765–1774.
9. Pariante, Carmine M., and Stafford L. Lightman. “The HPA Axis in Major Depression: Classical Theories and New Developments.” Trends in Neurosciences, vol. 31, no. 9, 2008, pp. 464–468.
10. Upthegrove, Rachel, et al. “Inflammation and Schizophrenia: Mechanisms and Clinical Implications.” Current Topics in Behavioral Neurosciences, vol. 44, 2020, pp. 147–163.
11. World Health Organization. Mental Disorders. WHO, 2023, https://www.who.int/news-room/fact-sheets/detail/mental-disorders
12. Bullmore, Edward. The Inflamed Mind: A Radical New Approach to Depression. Picador, 2018.
13. Dantzer, Robert, et al. “From Inflammation to Sickness and Depression: When the Immune System Subjugates the Brain.” Nature Reviews Neuroscience, vol. 9, no. 1, 2008, pp. 46–56.
14. Felger, Jennifer C., and Andrew H. Miller. “Cytokine Effects on the Basal Ganglia and Dopamine Function: The Subcortical Source of Inflammatory Malaise.” Frontiers in Neuroendocrinology, vol. 35, no. 1, 2014, pp. 31–42.
15. Felger, Jennifer C., and Andrew H. Miller. “Targeting Inflammation in the Treatment of Depression: Current Concepts and Future Directions.” Nature Reviews Immunology, vol. 20, no. 11, 2020, pp. 687–701.
16. Kiecolt-Glaser, Janice K., et al. “Psychoneuroimmunology: Psychological Influences on Immune Function and Health.” Journal of Consulting and Clinical Psychology, vol. 70, no. 3, 2002, pp. 537–547.
17. Leonard, Brian E. “Inflammation, Depression and Dementia: Are They Connected?” Neurochemical Research, vol. 32, no. 10, 2007, pp. 1749–1756.
18. Maes, Michael. “Evidence for an Immune Response in Major Depression: A Review and Hypothesis.” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 19, no. 1, 1995, pp. 11–38.
19. Miller, Andrew H., et al. “Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression.” Biological Psychiatry, vol. 65, no. 9, 2009, pp. 732–741.
20. Raison, Charles L., et al. “Inflammation, Sanity, and Stupidity: Why the Immune System Subjugates the Brain.” Behavioral and Brain Sciences, vol. 29, no. 1, 2006, pp. 1–56.
21. Raison, Charles L., et al. “Inflammatory Biomarkers as Predictors of Antidepressant Response.” Neuroscience Letters, vol. 520, no. 2, 2012, pp. 199–203.
22. Rosenblat, Joshua D., et al. “Inflammation as a Neurobiological Target for Bipolar Disorder.” Journal of Affective Disorders, vol. 225, 2018, pp. 696–706.
23. Smith, Ronald S. “The Macrophage Theory of Depression.” Medical Hypotheses, vol. 35, no. 4, 1991, pp. 298–306.
24. Stahl, Stephen M. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed., Cambridge UP, 2021.
25. Yirmiya, Raz, et al. “Depression as a Microglial Disease.” Trends in Neurosciences, vol. 38, no. 10, 2015, pp. 637–658.
26. Beurel, Emmanuel, et al. “Inflammation and Depression: Why Postmortem Studies Are Important.” Neuroscience, vol. 330, 2016, pp. 9–16.
27. Müller, Norbert. “Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations.” Schizophrenia Bulletin, vol. 44, no. 5, 2018, pp. 973–982.
28. Goldsmith, Daniel R., et al. “Inflammatory Markers and Antidepressant Response: A Meta-Analysis.” Brain, Behavior, and Immunity, vol. 95, 2021, pp. 53–64.
29. Troubat, Raphaël, et al. “Neuroinflammation and Depression: A Review.” European Journal of Neuroscience, vol. 53, no. 1, 2021, pp. 151–171.
30. Marx, Wolfgang, et al. “Inflammation and Major Depressive Disorder: The State of the Art and Future Directions.” Molecular Psychiatry, vol. 28, no. 1, 2023, pp. 224–250.
31. Cai, H., et al. “Neuroinflammation in Depression: Mechanisms and Therapeutic Opportunities.” Signal Transduction and Targeted Therapy, vol. 9, 2024, Article 58.
